Your browser doesn't support javascript.
loading
Management of chronic myeloid leukemia during pregnancy: a retrospective analysis at a single center
Moura, Ariella Cássia de; Delamain, Márcia Torresan; Duarte, Gislaine Borba Oliveira; Lorand-Metze, Irene; Souza, Cármino Antônio de; Barbosa Pagnano, Kátia Borgia.
  • Moura, Ariella Cássia de; Universidade Estadual de Campinas. Campinas. BR
  • Delamain, Márcia Torresan; Universidade Estadual de Campinas. Campinas. BR
  • Duarte, Gislaine Borba Oliveira; Universidade Estadual de Campinas. Campinas. BR
  • Lorand-Metze, Irene; Universidade Estadual de Campinas. Campinas. BR
  • Souza, Cármino Antônio de; Universidade Estadual de Campinas. Campinas. BR
  • Barbosa Pagnano, Kátia Borgia; Universidade Estadual de Campinas. Campinas. BR
Hematol., Transfus. Cell Ther. (Impr.) ; 41(2): 125-128, Apr.-June 2019. tab
Article in English | LILACS | ID: biblio-1012180
ABSTRACT
ABSTRACT We analyzed the management and outcomes of pregnancies of patients with chronic myeloid leukemia at a single center over fifteen years. Among the 203 CML female patients, there were ten pregnancies in seven women, all of them not planned. In three cases, the chronic myeloid leukemia diagnosis was made during pregnancy. Five patients received tyrosine kinase inhibitors in the first weeks of pregnancy and the drug was interrupted until delivery. One patient lost complete cytogenetic response, and two patients lost the hematological response. A patient with a stable major molecular response had two successful pregnancies without loss of response. There were four premature births. There were no maternal adverse events, fetal malformation or death. All patients received Interferon-alpha during gestation, and two received hydroxyurea for a short period. Leukapheresis was performed in two patients for hyperleukocytosis control. One patient with sickle cell disease died from disease progression six months after delivery.

Conclusions:

The tyrosine kinase inhibitors ministration should be interrupted during pregnancy. Patients should be advised to achieve a stable and deep molecular response if they plan to conceive, to avoid the risk of disease progression.
Subject(s)


Full text: Available Index: LILACS (Americas) Main subject: Pregnancy / Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Interferon-alpha / Imatinib Mesylate / Dasatinib / Hydroxyurea Type of study: Risk factors Limits: Female / Humans / Pregnancy Language: English Journal: Hematol., Transfus. Cell Ther. (Impr.) Journal subject: Hematologia / TransfusÆo de Sangue Year: 2019 Type: Article Affiliation country: Brazil Institution/Affiliation country: Universidade Estadual de Campinas/BR

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Main subject: Pregnancy / Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Interferon-alpha / Imatinib Mesylate / Dasatinib / Hydroxyurea Type of study: Risk factors Limits: Female / Humans / Pregnancy Language: English Journal: Hematol., Transfus. Cell Ther. (Impr.) Journal subject: Hematologia / TransfusÆo de Sangue Year: 2019 Type: Article Affiliation country: Brazil Institution/Affiliation country: Universidade Estadual de Campinas/BR